Imaging with a new radioactive tracer for solid tumors
Official title: Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT
Run by M.D. Anderson Cancer Center · NCT03604315 · Data updated 2026-11-12
This study is testing a new imaging method using a special radioactive tracer to see if it can help find tumor cells in patients with solid tumors like ovarian and breast cancers, while also looking at how safe it is and how it relates to certain genetic factors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 300 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | December 18, 2018 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | October 6, 2026 |
| Trial ID | NCT03604315 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with known or suspected solid tumors who have at least one measurable lesion.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or unable to tolerate imaging procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase I trial evaluates the effectiveness of fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) in detecting tumor cells in patients with various solid tumors, including ovarian and breast cancers. The study aims to assess the safety of the tracer and its correlation with genetic factors such as BRCA mutation status and PARP-1 activity. Patients will undergo imaging scans before and after treatment initiation to monitor changes in tracer uptake, providing insights into tumor behavior and treatment response.
Why it matters
Potential benefit: If successful, this study could enhance the detection and monitoring of solid tumors, leading to improved treatment strategies for patients.
How similar studies have gone: Other studies using novel imaging agents have shown promise, but this specific approach with fluorine F 18 fluorthanatrace is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of known or suspected solid tumor. * At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \[CT\], magnetic resonance imaging \[MRI\], ultrasound, fludeoxyglucose \[FDG\] PET/CT). Exclusion Criteria: * Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \< 2 weeks prior to screening as standard of care. * Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. * Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Where it's running
-
M D Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Lilie L Lin — M.D. Anderson Cancer Center
- Study coordinator: Lilie Lin
- Email: lllin@mdanderson.org
- Phone: 713-563-2300
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
Investigating blood cancer risks in patients with ovarian and other solid tumors
This study is trying to see if certain cancer treatments for ovarian and other solid tumors can increase the risk of blood cancers in patients.
-
IGFBP-2 vaccine after platinum to slow ovarian cancer recurrence
This study tests whether giving an IGFBP-2 vaccine after one carboplatin dose can help prevent progression of ovarian, fallopian tube, or primary peritoneal cancer that has shown serologic recurrence.
-
Automated physical activity program for cancer patients
This study is testing whether a personalized exercise program using wearable technology can help cancer patients be more active compared to regular exercise advice.
-
Using cryocompression and cilostazol to prevent nerve damage from chemotherapy in women with gynecological cancers
This study is testing if using cryocompression therapy alone or with a medication called cilostazol can help prevent nerve damage from chemotherapy in women with gynecological cancers.
-
Using MUC1-activated T cells to treat resistant ovarian cancer
This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.